Head of Life Sciences, IP Group Australia
| Role | Organisation | Sources |
|---|---|---|
| CEO (former) | RAGE Biotech | Startup Daily, SmartCompany |
| Head of Life Sciences | IP Group Australia | Brandon BioCatalyst portfolio, Startup Daily |
| Life Sciences Lead (former) | IP Group Australia | Startup Daily, SmartCompany, Brandon Capital portfolio |
| Director | Ankere Therapeutics | Brandon Capital portfolio, Brandon BioCatalyst portfolio, Startup Daily |
Stories naming Dr Siro Perez. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Atisama Therapeutics reports its Phase 1 trial of RB042 advancing into multiple ascending dose cohorts, and appoints experienced biopharma executive Bernard Coulie as chair of its board.
Weekly roundup of eight raises totalling $572.12 million, led by Firmus's $500 million round; RAGE Biotech, SunDrive, Number 8 Bio, Fabra, Keeyu, MyGig and Drone-Hand also funded, plus two RAGE Biotech executive appointments.
Also SmartCompany·Startup Daily·Startup Daily·Startup Daily·Startup Daily·Startup Daily·Business News Australia
Melbourne biotech RAGE Biotech has raised a $29 million Series A, with IP Group Australia and Hostplus leading, to fund human trials of its lung disease therapy; new executives were appointed.
Also Startup Daily
Biotech startup Ankere Therapeutics launches with a $10 million seed round co-led by IP Group and Brandon Capital to develop inflammatory lung disease therapies, building on research from Monash and UniSA scientists.
Also Brandon Capital portfolio·Startup Daily·@AuManufacturing